Navigation Links
SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
Date:3/11/2009

BOTHELL, Wash., March 11 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today reported financial results for the three and twelve months ended December 31, 2008. The Company will host a live conference call today, March 11, 2009, at 11:30 a.m. (Eastern Daylight Time).

"Last year was an important period for SCOLR Pharma," said President and CEO Bruce S. Morra, Ph.D., M.B.A. "Utilizing our unique CDT(R) platforms, we made significant progress advancing our two primary over-the-counter (OTC) drug candidates, ibuprofen and pseudoephedrine, through clinical development. During the second half of the year, we reported very positive top-line data from the pivotal Phase III trial of our 12 hour CDT 600 mg controlled release (CR) ibuprofen. We are encouraged by the increased interest in our ibuprofen product engendered by this data, leading to a number of new discussions with potential partners both within and outside the US. We remain optimistic that we will be able to reach agreement with suitable partner(s) to commercialize this product. We were also very pleased to report the FDA accepted our Abbreviated New Drug Application (ANDA) for our pseudoephedrine formulation for review. The FDA subsequently issued a Complete Response Letter for our pseudoephedrine application, which identified only minor deficiencies in the Chemistry and Manufacturing Controls section of the filing. None of the deficiencies cited by the FDA involve the safety or efficacy of the product and we are actively working to address the questions raised by the FDA and advance our pseudoephedrine product candidate toward approval.

"Further, there has been a significant effort within the Company to reduce expenses and closely manage our cash burn," Dr. Morra added. "In 2008, we were able to achieve a substantial decrease in total operating expenses compared with the prior year. In addition, we completed a lease termination and buyout tran
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
5. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
6. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
7. China Biopharma, Inc. Announces New Plan of Operation
8. Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing
9. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
10. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
11. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... 23, 2014  Having the right people at the ... accelerating business growth and achieving clinical and operational goals. ... Leadership Summit, July 20-22, 2014, in San ... executives and healthcare experts discussing how partnerships have positively ... President & Chief Executive Officer of Cape Regional Medical ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... 24 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the clinical development plan ... Ph.D., chairman and chief,executive officer, Ronald A. Martell, ...
... Ill., July 24 Sagent Pharmaceuticals, Inc.,a privately-held ... ceftazidime for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. ... dose vials and 6g pharmacy bulk package vials. ... in the United States were,approximately $45.7 million., ...
... Company reports double-digit sales and earnings growth, ... LLY ) today announced financial results for ... presented on a reported basis. Reported,results were prepared ... include all sales and expenses recognized by the,company ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2Lilly Reports Solid Second-Quarter Results 2Lilly Reports Solid Second-Quarter Results 3Lilly Reports Solid Second-Quarter Results 4Lilly Reports Solid Second-Quarter Results 5Lilly Reports Solid Second-Quarter Results 6Lilly Reports Solid Second-Quarter Results 7Lilly Reports Solid Second-Quarter Results 8Lilly Reports Solid Second-Quarter Results 9Lilly Reports Solid Second-Quarter Results 10Lilly Reports Solid Second-Quarter Results 11Lilly Reports Solid Second-Quarter Results 12Lilly Reports Solid Second-Quarter Results 13Lilly Reports Solid Second-Quarter Results 14Lilly Reports Solid Second-Quarter Results 15Lilly Reports Solid Second-Quarter Results 16Lilly Reports Solid Second-Quarter Results 17Lilly Reports Solid Second-Quarter Results 18Lilly Reports Solid Second-Quarter Results 19Lilly Reports Solid Second-Quarter Results 20Lilly Reports Solid Second-Quarter Results 21
(Date:7/23/2014)... Canada has issued a high health risk warning for ... the region due to forest fires. In the ... drifting eastward along normal wind patterns. Fire is ... from fires is not quite so obvious and its ... type of fire (forest, brush, crop, structure, tires, waste ...
(Date:7/23/2014)... DC -- The planet,s soil releases about 60 billion ... is far more than that released by burning fossil ... This enormous release of carbon is balanced by carbon ... other plant matter, as well as by the underground ... have documented that rising temperatures increase the rate of ...
(Date:7/23/2014)... local and national governments struggle to deal with ever-growing ... refining the picture of just how much there is ... ACS journal Environmental Science & Technology , their ... developed countries discard floods into just seven developing countries ... who live there. , Knut Breivik and colleagues note ...
Breaking Biology News(10 mins):Climate change and the soil 2
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... sugar may be enough to cool a hot temper, at least ... found that people who drank a glass of lemonade sweetened with ... than did people who consumed lemonade with a sugar substitute. ... simple sugar found in the bloodstream that provides energy for the ...
... 30, 2010Access to quality reproductive healthcare for women around ... human rights, freedom, equity, and right to control her ... Health in the current issue of Journal of Women,s ... Inc., explores the compelling medical, socioeconomic, and gender-based factors ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Ensuring the rights of women worldwide to reproductive health care 2
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: